PIH1D1 Antibody

What is PIH1D1 and what cellular functions does it mediate?

PIH1D1 (PIH1 domain containing 1) serves as a scaffold protein within the R2TP cochaperone complex, which plays a critical role in the assembly of multisubunit machines including small nucleolar ribonucleoproteins (snoRNPs), RNA polymerase II, and the mTORC1 and SMG1 kinase complexes . The protein functions through multiple mechanisms:

• It recruits the SWI/SNF complex to the core promoter of rRNA genes, enhancing pre-rRNA transcription

• It mediates the interaction of TELO2 with the R2TP complex, which is necessary for the stability of MTOR and SMG1

• It positively regulates the assembly and activity of the mTORC1 complex

• It contributes to DNA damage response pathways involving p53 stabilization and activation

The multifunctional nature of PIH1D1 makes it an important target for studies investigating cellular assembly processes and signaling pathways.

What is the molecular structure and key domains of PIH1D1?

PIH1D1 is a 290 amino acid protein with a calculated molecular weight of 32 kDa, though it is typically observed at approximately 39 kDa in experimental conditions . The protein contains several functionally distinct domains:

The PIH-N domain preferentially binds to highly acidic phosphorylated proteins containing a conserved DpSDD phosphopeptide motif, such as that found in TEL2 . This phosphorylation-dependent recognition mechanism defines how the R2TP complex selects its substrates for assembly.

Why is PIH1D1 important in cancer and cellular stress research?

PIH1D1's involvement in multiple cellular processes makes it relevant to cancer and cellular stress research for several reasons:

• DNA damage response: Depletion of PIH1D1 results in reduced p53 levels and loss of Ser15 phosphorylation after DNA damage, suggesting a role in genome stability maintenance .

• Protein complex assembly: As a core component of the R2TP complex, PIH1D1 is involved in the assembly and stability of complexes related to growth signaling (mTORC1) and RNA processing (snoRNPs) .

• Cell cycle progression: PIH1D1's interactions with various cellular components influence cell proliferation pathways, potentially contributing to cancer development when dysregulated .

• Stress response: The R2TP complex containing PIH1D1 is implicated in cellular adaptation to various stresses, including nutrient limitation and proteotoxic stress .

Understanding PIH1D1's functions may provide insights into cancer biology and potential therapeutic targets in stress response pathways.

What applications are most suitable for PIH1D1 antibodies in research?

PIH1D1 antibodies have been validated for several research applications, with varying optimal conditions:

Researchers should titrate the antibody in their specific experimental system to achieve optimal results, as sensitivity may vary between different tissue types and experimental conditions .

How should I design experiments to study PIH1D1 phosphorylation-dependent interactions?

When investigating PIH1D1's phosphorylation-dependent interactions, consider the following experimental design approach:

• Antibody selection:

  • Use PIH1D1 antibodies validated for immunoprecipitation applications

  • Consider domain-specific antibodies that distinguish N-terminal (phosphopeptide-binding) and C-terminal regions

• Experimental treatments:

  • Incorporate phosphatase treatments to confirm phosphorylation dependency

  • Include phosphatase inhibitors during cell lysis to preserve phosphorylation status

  • Consider using CK2 inhibitors, as CK2 is known to phosphorylate TEL2, a PIH1D1 interactor

• Mutation analysis:

  • Use PIH1D1 K64A mutant (disrupts phosphopeptide binding) as a negative control

  • Compare wild-type PIH1D1 with phospho-binding mutants in rescue experiments

  • Create phosphomimetic mutations in potential interacting partners

• Validation approaches:

  • Combine co-immunoprecipitation with Western blot analysis

  • Verify interactions using reciprocal IP experiments

  • Perform in vitro binding assays with recombinant proteins

The phosphopeptide binding domain (PIH-N) of PIH1D1 preferentially binds to highly acidic phosphorylated proteins containing the conserved DpSDD motif, making this interaction mechanism central to its role in the R2TP complex .

What controls are essential when performing immunostaining with PIH1D1 antibodies?

When conducting immunostaining experiments with PIH1D1 antibodies, include these essential controls:

• Positive tissue/cell controls:

  • Human tissues: lung, ovary, testis, and placenta show reliable PIH1D1 expression

  • Cell lines: HeLa and A431 cells consistently express PIH1D1

• Negative controls:

  • Primary antibody omission control

  • Isotype control (matching host species and immunoglobulin class)

  • siRNA-mediated PIH1D1 knockdown samples as biological negative controls

• Antigen retrieval validation:

  • Compare TE buffer (pH 9.0) and citrate buffer (pH 6.0) for optimal epitope exposure

  • Document the specific retrieval method used in your experimental system

• Antibody specificity controls:

  • Test multiple antibodies targeting different PIH1D1 epitopes

  • Consider peptide competition assays to confirm binding specificity

  • Include Western blot validation alongside immunostaining

• Subcellular localization verification:

  • Use co-staining with markers of relevant subcellular compartments

  • Compare nuclear versus cytoplasmic distribution in different cell types

  • Document exposure settings and image acquisition parameters

The comprehensive use of these controls ensures reliable interpretation of PIH1D1 immunostaining results and facilitates comparison with published findings.

How can I investigate PIH1D1's role in the R2TP complex assembly process?

To study PIH1D1's function in R2TP complex assembly, employ the following methodological approaches:

• Domain mapping experiments:

  • Use truncation mutants to identify regions responsible for specific interactions

  • The N-terminal ~250 amino acids bind phosphorylated TEL2, while the C-terminal region interacts with RUVBL1, RUVBL2, and RPAP3

  • Create point mutations in key residues (e.g., K57A, K64A in the PIH-N domain) to disrupt specific interactions

• Biochemical fractionation:

  • Perform size exclusion chromatography to separate intact complexes from subcomplexes

  • Analyze fractions by Western blot for PIH1D1 and other R2TP components

  • Compare complex composition in wild-type versus PIH1D1-depleted cells

• Sequential immunoprecipitation:

  • First, immunoprecipitate with PIH1D1 antibody

  • Elute under mild conditions

  • Perform second immunoprecipitation with antibodies against specific complex components

  • Analyze resulting complexes by Western blot or mass spectrometry

• Structural analysis integration:

  • Combine antibody-based findings with published structural data

  • Use deletion mutants to test structural predictions

  • Consider crosslinking approaches to capture transient interactions

• Cell-based functional assays:

  • Complement PIH1D1 knockdown cells with wild-type or mutant constructs

  • Measure functional readouts associated with R2TP activities (e.g., snoRNP assembly, PIKK stability)

  • Compare acute versus chronic depletion to distinguish direct versus indirect effects

These approaches will help dissect the step-wise assembly of the R2TP complex and PIH1D1's role as a scaffold protein in this process.

What methodological approaches can resolve contradictions in PIH1D1 functional studies?

When faced with contradictory findings regarding PIH1D1 function, implement these methodological approaches:

By systematically addressing these methodological variables, researchers can determine whether contradictory findings reflect genuine biological differences or technical factors.

How can I distinguish between PIH1D1's roles in different cellular complexes?

To differentiate PIH1D1's functions in various cellular complexes, implement these specialized techniques:

• Complex-specific immunoprecipitation:

  • Use antibodies against unique components of each complex (e.g., TELO2 for TTT complex, RPAP3 for R2TP)

  • Analyze PIH1D1 association with each complex by Western blot

  • Compare complex compositions across different cellular conditions

• Proximity-based labeling techniques:

  • Generate BioID or TurboID fusions with PIH1D1

  • Identify proximity-dependent biotinylated proteins by mass spectrometry

  • Compare biotinylation patterns under different cellular conditions

• Mutational analysis:

  • Create PIH1D1 mutants that disrupt specific interactions:

    • K64A mutation disrupts phospho-TEL2 binding

    • Design mutations in the C-terminal region to disrupt RUVBL1/2 binding

  • Rescue PIH1D1-depleted cells with these mutants

  • Measure complex-specific functional readouts

• Microscopy-based approaches:

  • Perform co-localization studies with markers of different complexes

  • Use structured illumination or super-resolution microscopy for detailed analysis

  • Implement FRET or FLIM techniques to detect direct interactions

• Functional readouts:

  • Measure distinct outcomes associated with each complex:

    • snoRNP assembly and function

    • PIKK stability (mTOR, SMG1)

    • Pre-rRNA transcription

    • DNA damage response (p53 stability)

These approaches allow researchers to dissect PIH1D1's multifaceted roles in different cellular processes through its participation in distinct protein complexes.

What are common technical challenges with PIH1D1 Western blotting and their solutions?

Researchers frequently encounter these challenges when performing Western blot for PIH1D1:

For optimal results when detecting PIH1D1 by Western blot, use RIPA buffer with protease inhibitors for lysis, load 20-50 μg total protein, use 10-12% SDS-PAGE gels, and follow manufacturer's recommended antibody dilutions .

How can I validate the specificity of a PIH1D1 antibody for my experimental system?

To comprehensively validate a PIH1D1 antibody for your specific research application:

• Genetic validation:

  • Perform siRNA-mediated knockdown or CRISPR/Cas9 knockout of PIH1D1

  • Compare antibody signal between control and knockdown/knockout samples

  • Signal reduction confirms specificity

• Overexpression validation:

  • Transfect cells with tagged PIH1D1 construct

  • Detect both endogenous and overexpressed protein

  • Confirm that antibody detects overexpressed protein at the expected size

• Multiple antibody comparison:

  • Test antibodies from different sources or targeting different epitopes

  • Compare staining patterns and band detection

  • Consistent results across antibodies support specificity

• Cross-species reactivity assessment:

  • Test antibody in samples from multiple species if cross-reactivity is claimed

  • Compare sequence homology in the antibody epitope region

  • Document species-specific differences in detection sensitivity

• Application-specific validation:

  • For WB: Confirm single band of expected size (~39 kDa)

  • For IHC/IF: Verify subcellular localization matches published data

  • For IP: Confirm enrichment of PIH1D1 in immunoprecipitated sample

• Control samples:

  • Include positive control samples with known PIH1D1 expression (HeLa, A431 cells, human testis tissue)

  • Use appropriate negative controls for each application

Thorough validation ensures reliable results and facilitates comparison with published findings.

What factors affect PIH1D1 antibody selection for specific research applications?

When selecting a PIH1D1 antibody for your research, consider these critical factors:

• Application compatibility:

  • Not all antibodies work equally well across applications

  • Check validation data for your specific application (WB, IHC, IF, IP)

  • Review published studies using the antibody for your application

• Epitope considerations:

  • N-terminal antibodies: Target the phosphopeptide binding domain

  • C-terminal antibodies: Target the region interacting with RUVBL1/2

  • Consider whether protein interactions might mask your epitope of interest

• Species reactivity:

  • Verify cross-reactivity with your experimental species

  • Check sequence homology in the immunogen region

  • Predicted reactivity: Human (100%), Rat (93%), Mouse (varies), Cow (79%), Dog (93%)

• Antibody format:

  • Monoclonal: Higher specificity, less lot-to-lot variation

  • Polyclonal: Higher sensitivity, recognize multiple epitopes

  • Consider conjugated antibodies for direct detection methods

• Validation data review:

  • Examine images of Western blots, IHC, and IF provided by manufacturer

  • Check for validation using knockout/knockdown controls

  • Review citations of the antibody in published literature

• Experimental conditions:

  • Buffer compatibility (phosphate vs. Tris-based)

  • Storage requirements (-20°C, glycerol content)

  • Stability and recommended handling

Selecting the appropriate antibody based on these criteria will significantly improve experimental outcomes and data reliability.

How can PIH1D1 antibodies be used to investigate cancer-related signaling pathways?

PIH1D1 antibodies provide valuable tools for exploring cancer-related signaling pathways through these methodological approaches:

• PIH1D1-mTOR pathway analysis:

  • Use PIH1D1 antibodies to immunoprecipitate associated complexes

  • Analyze mTORC1 assembly and stability in cancer cells

  • Investigate how PIH1D1 levels correlate with mTOR signaling activity

  • Experimental design: Compare PIH1D1-mTOR interactions in drug-resistant versus sensitive cell lines

• DNA damage response studies:

  • Monitor PIH1D1-p53 interactions before and after genotoxic stress

  • Assess how PIH1D1 depletion affects p53 levels and phosphorylation status

  • Investigate potential roles in chemotherapy resistance mechanisms

  • Experimental design: Track PIH1D1 subcellular localization during DNA damage response

• Cancer tissue analysis:

  • Perform IHC on tumor microarrays using validated PIH1D1 antibodies

  • Correlate expression patterns with clinical parameters and patient outcomes

  • Compare expression in tumor versus adjacent normal tissue

  • Experimental design: Quantitative analysis of nuclear versus cytoplasmic PIH1D1 staining

• R2TP complex alterations in cancer:

  • Analyze PIH1D1-dependent complex formation in various cancer types

  • Investigate how oncogenic stress affects PIH1D1 interactions

  • Study how PIH1D1 levels influence cancer cell sensitivity to chaperone inhibitors

  • Experimental design: Comparative immunoprecipitation studies across cancer cell lines

These approaches can reveal how PIH1D1's functions in protein complex assembly and stability contribute to cancer pathogenesis and therapy responses.

What novel experimental approaches can enhance PIH1D1 functional studies?

Innovative methodological approaches to advance PIH1D1 functional studies include:

• CRISPR-based genomic tagging:

  • Insert fluorescent or affinity tags at the endogenous PIH1D1 locus

  • Monitor dynamics of endogenous PIH1D1 in live cells

  • Track interactions with partner proteins under physiological conditions

  • Advantage: Avoids overexpression artifacts and maintains native regulation

• Proximity-dependent labeling technologies:

  • Generate BioID, TurboID, or APEX2 fusions with PIH1D1

  • Map the spatiotemporal interactome of PIH1D1 under different conditions

  • Identify transient or weak interactions often missed by immunoprecipitation

  • Experimental design: Compare interactomes in normal versus stressed conditions

• Single-molecule imaging approaches:

  • Visualize PIH1D1-containing complexes using super-resolution microscopy

  • Track complex assembly/disassembly kinetics in real-time

  • Analyze diffusion dynamics to infer complex size and composition

  • Application: Monitoring PIH1D1 behavior during stress response or cell cycle

• Domain-specific antibody development:

  • Generate antibodies specific to the PIH-N domain

  • Create phospho-specific antibodies targeting PIH1D1 phosphorylation sites

  • Develop conformation-specific antibodies that recognize specific binding states

  • Utility: Distinguishing different functional pools of PIH1D1 in cells

• Optogenetic control of PIH1D1 interactions:

  • Engineer light-inducible PIH1D1 binding domains

  • Temporally control specific interactions with partner proteins

  • Dissect the sequence of events in complex assembly

  • Application: Determining the kinetics and hierarchy of R2TP complex formation

These cutting-edge approaches can provide mechanistic insights into PIH1D1 function with unprecedented spatial and temporal resolution.

How can we integrate PIH1D1 antibody data with other omics approaches?

To achieve comprehensive understanding of PIH1D1 biology, integrate antibody-based findings with other omics data through these methodological approaches:

• Immunoprecipitation-mass spectrometry (IP-MS) integration:

  • Perform PIH1D1 immunoprecipitation under various conditions

  • Identify interaction partners by mass spectrometry

  • Correlate with publicly available protein-protein interaction databases

  • Analysis approach: Compare interactomes across different cell types and conditions

• Proteogenomic correlation:

  • Measure PIH1D1 protein levels using validated antibodies

  • Correlate with mRNA expression data from RNA-seq

  • Identify post-transcriptional regulatory mechanisms

  • Experimental design: Multi-omics analysis of matched clinical samples

• Phosphoproteomics integration:

  • Use phospho-specific antibodies to track PIH1D1 phosphorylation

  • Correlate with global phosphoproteomic data

  • Map kinase-substrate relationships affecting PIH1D1 function

  • Analysis approach: Kinase activity inference from phosphorylation patterns

• Functional genomics correlation:

  • Compare PIH1D1 antibody-based localization/interaction data with CRISPR screen results

  • Identify functional dependencies related to PIH1D1 complexes

  • Correlate with drug sensitivity profiles

  • Experimental design: Synthetic lethality screens in PIH1D1-depleted backgrounds

• Multi-dimensional data visualization:

  • Create integrated network models incorporating antibody-derived interaction data

  • Visualize temporal dynamics of PIH1D1 complexes

  • Develop predictive models of PIH1D1 function in different contexts

  • Analysis tools: Cytoscape for network visualization, R or Python for multi-omics integration

This integrated approach provides a systems-level understanding of PIH1D1 biology that cannot be achieved through antibody-based methods alone.